Shanghai Ark Biopharmaceutical…announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for AK3280, a novel anti-ﬁbrotic therapy for the treatment of idiopathic pulmonary ﬁbrosis (IPF)

AK3280 - Ark Biosci

Feb 11, 2026